Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global phase III trial of Ad5-nCoV in adults
ChiCTR2100044249Phase 3Recruiting
- Sponsor
- Canadian Center for Vaccinology
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Canadian Center for Vaccinology. Primary endpoints: Efficacy against PCR-confirmed COVID-19 from Day 28 to Week 52 and Incidence of SAE and MAE up to Week 52. Started Sep 2020; status: recruiting.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100044249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044249.